Basis: Trailing twelve months (TTM net income over the latest quarterly balance sheet). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the return on assets (ROA) high or low?
The return on assets (ROA) of -91.66% is 208% below its 5-year average of -29.79%, near the low end of its 5-year range (-91.66%–-9.42%).
88.23% below its 12-month average of -48.70%.
Reported quarterly return on assets; no daily interpolation. Q2 FY2026 (2026-06-30): -22.04%.
RETURN ON ASSETS (ROA)
-91.66%
RETURN ON ASSETS (ROA) AVG TTM
-48.70%
RETURN ON ASSETS (ROA) AVG 3Y
-37.97%
RETURN ON ASSETS (ROA) AVG 5Y
-29.79%
RETURN ON ASSETS (ROA) AVG 10Y
N/A
RETURN ON ASSETS (ROA) AVG 15Y
N/A
RETURN ON ASSETS (ROA) AVG 20Y
N/A
CURRENT VS TTM AVG
-88.23%
CURRENT VS 3Y AVG
-141.43%
CURRENT VS 5Y AVG
-207.70%
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-32.27%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
-184.08%
vs the sector median at left
PMV Pharmaceuticals, Inc.
Market Cap
$85.86M
Return on Assets (ROA)
-91.66%
TTM Avg
-48.70%
3Y Avg
-37.97%
5Y Avg
-29.79%
Market Cap
$87.27M
Return on Assets (ROA)
-169.86%
TTM Avg
-100.47%
3Y Avg
-69.80%
5Y Avg
-64.10%
Market Cap
$84.13M
Return on Assets (ROA)
-43.13%
TTM Avg
-80.45%
3Y Avg
-58.18%
5Y Avg
-65.67%
Market Cap
$87.85M
Return on Assets (ROA)
-79.38%
TTM Avg
41.63%
3Y Avg
-36.06%
5Y Avg
-44.84%
Market Cap
$87.96M
Return on Assets (ROA)
8.52%
TTM Avg
11.64%
3Y Avg
-8.81%
5Y Avg
-6.61%
Market Cap
$82.59M
Return on Assets (ROA)
-74.48%
TTM Avg
-208.94%
3Y Avg
-35981.57%
5Y Avg
-24064.76%
Market Cap
$82.53M
Return on Assets (ROA)
-109.51%
TTM Avg
-695.26%
3Y Avg
-854.30%
5Y Avg
-733.67%
Market Cap
$82.47M
Return on Assets (ROA)
-107.29%
TTM Avg
-60.42%
3Y Avg
-51.23%
5Y Avg
-39.69%
Market Cap
$89.44M
Return on Assets (ROA)
-86.56%
TTM Avg
-66.44%
3Y Avg
-84.84%
5Y Avg
-75.69%
| NAME | MARKET CAP | RETURN ON ASSETS (ROA) | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| PMV Pharmaceuticals, Inc. (PMVP) | $85.86M | -91.66% | -48.70% | -37.97% | -29.79% |
| Neumora Therapeutics, Inc. Common Stock (NMRA)vs › | $87.27M | -169.86% | -100.47% | -69.80% | -64.10% |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.13M | -43.13% | -80.45% | -58.18% | -65.67% |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $87.85M | -79.38% | 41.63% | -36.06% | -44.84% |
| CareCloud, Inc. (CCLD)vs › | $87.96M | 8.52% | 11.64% | -8.81% | -6.61% |
| ProMIS Neurosciences, Inc. (PMN)vs › | $82.59M | -74.48% | -208.94% | -35981.57% | -24064.76% |
| Telomir Pharmaceuticals, Inc. Common Stock (TELO)vs › | $82.53M | -109.51% | -695.26% | -854.30% | -733.67% |
| Cardiff Oncology, Inc. (CRDF)vs › | $82.47M | -107.29% | -60.42% | -51.23% | -39.69% |
| electroCore, Inc. (ECOR)vs › | $89.44M | -86.56% | -66.44% | -84.84% | -75.69% |
| LENSAR Inc (LNSR)vs › | $82.29M | 49.88% | -47.68% | -37.92% | -34.36% |
ROA
-91.7%
ROE
-105.2%
ROA = Net Income / Total Assets
Return on assets measures how efficiently a company generates profit from its total assets.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | RETURN ON ASSETS (ROA) |
|---|---|
| 2025-12-31 | -66.70% |
| 2024-12-31 | -30.69% |
| 2023-12-31 | -27.35% |
| 2022-12-31 | -27.12% |
| 2021-12-31 | -17.45% |
| 2020-12-31 | -9.42% |
| 2019-12-31 | -24.61% |
| 2018-12-31 | -27.64% |
